SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
Year: 2021
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF. However, the efficacy of SGLT2 inhibitors in secondary endpoints of randomized trials and in subgroups of HF patients is not well known. METHODS: We performed a systematic review and meta-analysis of placebo-controlled, randomized trials of SGLT2 inhibitors in patients with HF. PubMed, Embase, and Cochrane databases were searched for trials published up to January 21, 2021. Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Hazard ratios (HRs) with 95% CI were pooled across trials. The primary endpoints of interest were all-cause and cardiovascular mortality. RESULTS: =0%) were significantly lower in patients treated with SGLT2 inhibitors compared with placebo. The composite of cardiovascular mortality, HF hospitalizations, or urgent visits for HF was significantly reduced with SGLT2 inhibitors in all the following subgroups: male, female, age < 65, age ≥ 65, race - Black and White, estimated glomerular filtration rate (eGFR) <60, eGFR ≥60, New York Heart Association (NYHA) class II, NYHA ≥III, and HF with preserved ejection fraction. INTERPRETATION: In patients with HF, SGLT2 inhibitors significantly reduce all-cause and cardiovascular mortality compared with placebo. In addition, the composite of cardiovascular mortality or HF hospitalizations/urgent visits is reduced with SGLT2 inhibitors across subgroups of sex, age, race, eGFR, HF functional class, and ejection fraction.
Source: EClinicalMedicine
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: SGLT2 inhibitors, heart failure, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, sex differences, age differences, racial differences, estimated glomerular filtration rate, NYHA functional class, heart failure with preserved ejection fraction
Open Access status: gold
Estimated APC paid: $3,500
Funders: American Heart Association, Boehringer Ingelheim, Abbott Laboratories, Amgen, Eli Lilly and Company, Pfizer, Merck, Roche, Medtronic, Center for Social Inclusion, American College of Cardiology Foundation, Boston Scientific Corporation, Boston VA Research Institute, Medicines Company, HDL Therapeutics, Regado Biosciences, Eisai, Novo Nordisk, Biotronik, St. Jude Medical, School of Medicine
OpenAlex ID: W3172637229
